"Vaccines, Synthetic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Small synthetic peptides that mimic surface antigens of pathogens and are immunogenic, or vaccines manufactured with the aid of recombinant DNA techniques. The latter vaccines may also be whole viruses whose nucleic acids have been modified.
Descriptor ID |
D014614
|
MeSH Number(s) |
D12.776.828.868 D20.215.894.865 D23.050.865
|
Concept/Terms |
Vaccines, Synthetic- Vaccines, Synthetic
- Synthetic Vaccines
- Synthetic Immunogens
- Immunogens, Synthetic
Molecular Vaccines- Molecular Vaccines
- Vaccines, Molecular
- Vaccines, Chemical
- Chemical Vaccines
|
Below are MeSH descriptors whose meaning is more general than "Vaccines, Synthetic".
Below are MeSH descriptors whose meaning is more specific than "Vaccines, Synthetic".
This graph shows the total number of publications written about "Vaccines, Synthetic" by people in this website by year, and whether "Vaccines, Synthetic" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2004 | 0 | 2 | 2 |
2011 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Vaccines, Synthetic" by people in Profiles.
-
Adaptive immune responses in vaccinated patients with symptomatic SARS-CoV-2 Alpha infection. JCI Insight. 2022 03 08; 7(5).
-
Bovine papillomavirus-like particles presenting conserved epitopes from membrane-proximal external region of HIV-1 gp41 induced mucosal and systemic antibodies. Vaccine. 2013 Nov 04; 31(46):5422-9.
-
New weapons in the war on tuberculosis. Am J Ther. 2011 Jul; 18(4):e101-12.
-
Safety and immunogenicity of a polyvalent peptide C4-V3 HIV vaccine in conjunction with IL-12. AIDS. 2004 May 21; 18(8):1203-6.
-
Public health. A sound rationale needed for phase III HIV-1 vaccine trials. Science. 2004 Jan 16; 303(5656):316.